Nevertheless, therapy-induced variants, such as multiclonal BRCA2 reversion mutations or acquired AR alterations, have been identified exclusively in post-treatment metastatic biopsies or ctDNA in up to one-third of advanced PCa cases, reflecting both spatial and temporal heterogeneity. This evidence concerns the gene BRCA2 and posterior cortical atrophy.